biotechnology-biomarkers-systems-biology-2019-posters

Page 60

Biochemistry & Molecular Biology Journal

ISSN: 2471-8084

Internat i ona l Conference on

Biotechnology, Biomarkers

& Systems Biology

M a r c h 0 4 - 0 5 , 2 0 1 9

Am s t e r d a m , N e t h e r l a n d s

Biotechnology, Biomarkers & Systems Biology 2019

omatic BRCA testing (sBRCA) is emerging as a powerful tool to discover and identify more mutations in high serous ovarian

cancer patients. Despite its clinical utility, the availability of some technologies, able to enrich somatic mutation from FFPE

samples, still requires further adjustments before being completely considered as a validated routine assay. In the last two

years, my lab has experienced as the know-how on BRCA germline testing cannot be completely transferred to the somatic NGS

pipeline, being the two conditions very different. In light to better underline the main pitfalls and criticisms regarding sBRCA1/2

along with its usefulness in clinical routine setting, the present talk will cover the following issues: Why tumor BRCA1/2 testing

is important? What are the pitfalls that can strongly affect sBRCA testing; NGS technology needs to be complemented by other

Dx tools; how to solve these issues and accelerate the routine use of

sBRCA1/2

testing; the experience of my lab on 3000 ovarian

cancer women screened.

BRCA1/2 tumor testing and PARP-inhibitors: need

or fashion?

Ettore Capoluongo

UOA Diagnostica Molecolare e Genomica Fondazione Policlinico Gemelli, IRCCS, Italy

Università Cattolica del Sacro Cuore, Italy

Biochem Mol biol J 2019, Volume:5

DOI: 10.21767/2471-8084-C1-024